Compare iShares China Large-Cap ETF (FXI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs BIO-TECHNE Corp — how do they compare? iShares China Large-Cap ETF trades at $34.54, while BIO-TECHNE Corp trades at $71.78 (market cap $11.14B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while iShares China Large-Cap ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | TECH | |
|---|---|---|
52-Week High | $41.75 | $71.48 |
52-Week Low | $31.59 | $43.31 |
Market Cap | — | $11.14B |
Sector | — | Health |
Enterprise Value | — | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI is currently trading at $34.545, up 2.29% with strong technical momentum indicated by bullish moving averages and ADX signals. The ETF benefits from China's accelerating AI and manufacturing sectors, with recent news highlighting a $295 billion AI infrastructure plan and robust export growth. However, RSI readings above 89 suggest the ETF is significantly overbought near-term.
The outlook remains positive given China's strategic investments in technology and manufacturing, though investors face risks from US-China trade tensions and potential profit-taking after recent gains. Wall Street sentiment is cautiously optimistic as institutional flows respond to China's economic initiatives.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
